



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 19<sup>TH</sup> JUNE 2019 AT  
12.00pm

IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,  
ROYAL BLACKBURN HOSPITAL

### PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW) Mr N Fletcher (NF)	Medicines Information Manager, ELHT Director of Pharmacy ELHT
Mr J Vaughan (JV) Dr S Jackson (SJ) Mr A Gray (AG)	Commissioning Support Pharmacist NHS EL/BwD Clinical Commissioning Group MM Lead, GP EL Clinical Pharmacist, ELHT
Mrs C Dugdale (CD) Dr K Burch (KB)	Meds Management Pharmacist NHS BwD CCG Consultant Microbiologist ELHT

### IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

### 2019/073: APOLOGIES:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr D Gavan (DG)	Consultant Radiologist ELHT
Dr T Mackenzie (TM)	GP, EL CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

### 2019/074: DECLARATION OF INTEREST

None declared – relevant to agenda items.

### 2019/075: MINUTES OF MAY MEETING:

2019/068 Ertugliflozin Traffic Light should read GREEN  
Otherwise accepted as a correct record.

## **2019/076: MATTERS ARISING:**

**2019/025: ELHE: Respiratory Guidelines – Updated: COPD Guideline** - additional comments now included - Trelegy Ellipta as equal option with combination of two dry powder inhalers and reminder to stop SAMA if starting LAMA. To be uploaded to website.

**2019/040: Dry Eye Products Review Including New Product Requests – VisuXL® and Systane Balance®** - formulary summary and choices has been updated. Xailin HA (sodium hyaluronate 0.2%) will replace Evolve HA for new patients but Evolve HA will remain on formulary for existing patients. Blink Intensive Tears to be included for first line in primary care. To be uploaded to website.

**2019/041: Lutein & Oral Antioxidant Vitamin Supplements for Eye Conditions –** ophthalmology accept prescribing guidance. Accepted for use when ELMMB logo added. To be uploaded to website.

**2019/044: LMMG Recommendations (From Feb LMMG) - Out of Area Prescribing Position Statement** – adapted version to next meeting.

**2019/064: Formulary Updates - Tranexamic acid injection for topical use –** statement received from palliative care to support its change to a green traffic light for palliative patients. SJ to ask tissue viability / lead district nurse to write a procedure to support its use.

## **2019/077: LMMG CONSULTATIONS (for July LMMG)**

**Dementia Medicines Information Sheet - updated** – update reflects NICE guidance. ELHE support information sheet.

**Trans Female Gender Dysphoria Prescribing Information Sheet** – to support GPs prescribing in line with NHSE guidance. Safety concerns were expressed by clinicians with the high doses of hormones used long term and felt prescribing responsibility should remain with the specialist with appropriate monitoring.

**Trans Male Gender Dysphoria Prescribing Information Sheet** – to support GPs prescribing in line with NHSE guidance. Safety concerns were expressed by clinicians with the high doses of hormones used long term and felt prescribing responsibility should remain with the specialist with appropriate monitoring.

**Camouflage Products Position Statement** – concerns were raised that the statement does not fit with the Policy on Cosmetic Procedures. ELMMB has a local policy for camouflage products with exceptions to be considered as an IFR, and do not agree with this position statement.

**Agglomelatine New Medicine Assessment** – ELMMB support the proposed Black traffic light.

**Brivaracetam Assessment** – updated for children – ELMMB support the addition of children to the existing assessment and the traffic light change to amber.

## **Resolved: Comments to be sent to LMMG**

## **2019/078: LMMG Recommendations (From May LMMG)**

**Guidelines for Good Prescribing in Primary Care – updated** - accepted for use in ELHE.

**COPD Guideline - updated** – acknowledged by ELMMB. ELHE will continue to use local guideline.

**E-cigarettes Position Statement – updated** – accepted for use in ELHE.

## **2019/079: FORMULARY UPDATES**

**Ciprofloxacin/fluocinolone (Cetraxal Plus®) Ear drops** – added to formulary for use in procedures when a single dose of ciprofloxacin in the ear is required.

**Traffic Light: Red**

Ciprofloxacin/dexamethasone (Cilodex®) ear drops (bottles) will remain the choice for short courses.

Ciprofloxacin eye drops will no longer be used as ear drops – remove from formulary.

**Resolved: Formulary to be updated as above**

## **2019/080: CONTRACT AGREEMENTS – IMPACT ACROSS ICP**

Discussion took place on secondary care purchasing contracts and the impact this can have in Primary Care. An example was shared highlighting significant cost implications in primary care. It was suggested to get together outside the meeting to discuss a way forwards.

**Action: LR to follow up with NF outside the meeting**

## **2019/081: GUIDANCE ON MANAGEMENT OF CDs IN GP PRACTICES**

Guidance document for information to add as reference source on website

**Resolved: To be uploaded as reference source on website.**

## **2019/082: SELF CARE INFORMATION FOR WEBSITE**

ELMMB agreed that links to information on self-care to be added to website.

**Resolved: Links to information on self-care to be added to website.**

## **2019/083: NICE RECOMMENDATIONS (from May)**

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [TA578] is recommended as an option by NICE.

Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA579] is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580) is not recommended as an option by NICE.

**Traffic Light: BLACK**

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

**Traffic Light: BLACK**

### **2019/084: EAMS**

Vyndaqel (tafamidis) for treatment of transthyretin amyloidosis in adult patients with wild type or hereditary cardiomyopathy to reduce all-cause mortality and cardiovascular-related hospitalisation.

Atezolizumab in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

## **STANDING ITEMS**

### **2019/085: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – May 2019**

Minutes acknowledged

### **2019/086: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Feb 2019**

Minutes acknowledged

### **2019/087: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE ANNUAL REPORT 2018 -19**

Report acknowledged

### **2019/088: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – May 2019**

Minutes acknowledged

**DATE OF NEXT MEETING – July meeting cancelled – next meeting will be Wednesday 21<sup>st</sup> August 2019 12.30pm, Seminar Room 2, Learning & Development Centre, RBH.**

**Please note meetings have reverted back to 12.30pm – 2pm**

Dates for 2019: All 3<sup>rd</sup> Wednesday of the month starting at 12.30pm

21<sup>st</sup> August

18<sup>th</sup> September

16<sup>th</sup> October

20<sup>th</sup> November

18<sup>th</sup> December

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 19<sup>TH</sup> JUNE 2019**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/044</b>	<b>LMMG Recommendations (from Feb LMMG) – Out of area prescribing Position Statement – LR to adapt for ELHE</b>	LR/JV	Apr 19
<b>2019/064</b>	<b>Formulary Updates – Tranexamic acid – awaiting procedure to support green traffic light</b>	SJ	Aug 19
<b>2019/080</b>	<b>Contract Agreements – impact across ICP – LR &amp; NF to meet &amp; discuss ELMMB</b>	LR/NF	Aug 19